APEDs, Not Protein, Drive Organ Enlargement in Bodybuilders
MRI study finds APED-using bodybuilders have dramatically enlarged hearts and livers — natural bodybuilders show no such effect despite high protein intake.
Summary
A new MRI study from Maastricht University compared organ volumes in natural bodybuilders, drug-using bodybuilders, and recreational exercisers. Natural bodybuilders consumed roughly twice the protein of controls but showed no difference in visceral organ size. APED-using bodybuilders, however, had hearts averaging 44% larger and livers averaging 43% larger than controls. The findings directly challenge the idea that high protein diets cause organ hypertrophy, instead pointing squarely at performance-enhancing drugs — including anabolic steroids, growth hormone, and insulin — as the culprit behind the distended abdomens seen in elite competitive bodybuilding. This has important implications for clinicians evaluating athletes and for public health messaging around protein intake safety.
Detailed Summary
The phenomenon of visceromegaly — abnormal enlargement of internal organs — has become visually prominent in competitive bodybuilding, yet its cause has remained debated. Two leading suspects have been high protein intake and the use of appearance- and performance-enhancing drugs (APEDs). This study set out to disentangle those factors using objective imaging data.
Researchers at Maastricht University recruited 45 men divided into three groups: 15 recreationally active controls, 15 competitive natural bodybuilders, and 15 competitive APED-using bodybuilders. All underwent MRI to measure skeletal muscle and visceral organ volumes, DXA scans for lean mass, and completed 7-day food diaries. The design allowed direct comparison of groups with similar training intensity but differing drug use and protein intake.
The results were striking. Natural bodybuilders consumed 2.5 g of protein per kg of body mass daily — nearly double the controls' 1.4 g/kg — yet their organ volumes were statistically indistinguishable from controls. APED users, consuming 2.9 g/kg protein, showed dramatically enlarged organs: hearts averaged 1.20 L versus 0.83 L in controls, and livers averaged 2.57 L versus 1.79 L. Lean mass and muscle volume followed the same pattern, with APED users significantly exceeding both other groups.
The implications are clinically meaningful. High protein intake — even at levels well above typical recommendations — does not appear to drive organ hypertrophy. Clinicians evaluating athletes with organomegaly should consider APED use as the primary etiology. For the general public, these findings provide reassurance that protein-rich diets are not inherently harmful to organ size.
Caveats include the small sample size of 15 per group, the cross-sectional design which cannot establish causation, and the reliance on self-reported APED use and dietary intake. The summary is based on the abstract only, as the full text was not available.
Key Findings
- Natural bodybuilders eating 2.5 g protein/kg/day showed no organ enlargement versus controls.
- APED-using bodybuilders had hearts ~44% larger and livers ~43% larger than controls.
- High protein intake alone does not cause visceromegaly in resistance-trained men.
- APED use was associated with significantly greater lean mass (87.8 kg vs 72.7 kg vs 62.8 kg).
- MRI objectively confirmed organ hypertrophy is a drug effect, not a dietary or training effect.
Methodology
Cross-sectional study of 45 males (15 per group) using MRI to quantify skeletal muscle and visceral organ volumes and DXA for lean mass assessment. Dietary intake was captured via 7-day food diaries and APED use was self-reported by participants. Groups were age-matched (mean ages 29–31 years) to minimize confounding.
Study Limitations
The cross-sectional design prevents causal inference, and the sample size of 15 per group limits statistical power and generalizability. Self-reported APED use and dietary intake introduce potential recall and social desirability bias. This summary is based on the abstract only, as the full text was not available for review.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.